Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab.

Frequency of autoimmune diseases in first degree relatives of psoriatic patients compared with controls: A cross-sectional study

Background: Psoriasis is a chronic autoimmune skin disorder with relapsing erythematous scaling plaques and joint or nail involvement. A greater occurrence of other autoimmune diseases has been reported in these patients. Additionally, their family members are more likely to be diagnosed with psoriasis. The aimof this study is to assess the prevalence of certain autoimmune diseases in first deg...

Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up

The tumor necrosis factor-α (TNF-α) antagonists infliximab, adalimumab, and etanercept have been approved for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. Manifestations of demyelinating disease have been reported for patients receiving TNF-α antagonists. We describe a rare manifestation of a chronic inf...

Demyelinating disease in a patient with psoriatic arthritis and family history of

Evaluation of chronic kidney disease and associated factors in psoriasis patients at Razi hospital, Tehran, Iran

Background: Psoriasis is a chronic and recurrent inflammatory disease that involves skin, joints and different organ systems. It is associated with Multiple morbidities such as cardiovascular disorders, diabetes, hypertension, hyperlipidemia and chronic kidney disease (CKD). Due to the high importance of the association between psoriasis and CKD which results in major side effects the aim of th...

Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study

INTRODUCTION The aim was to investigate the frequency of neurological adverse events in patients with rheumatoid arthritis (RA) and spondylarthropathies (SpA) treated with tumor necrosis factor (TNF) α antagonists. METHODS Seventy-seven patients eligible for anti-TNFα therapy were evaluated. There were 36 patients with RA, 41 with SpA [24 psoriatic arthritis (PsA) and 17 with ankylosing spond...